Veracyte, Inc.
VCYTNASDAQHealthcareDiagnostics & Research
As of Oct 15, 2026 close
- Market cap
- $3.64B
- P/E (TTM)
- 31.82
- Forward P/E
- 15.73
- Dividend yield
- -
- 52-week range
- $29.46$60.91
- Volume (live)
- -
- Avg. volume (3M)
- 1.37M
Veracyte (VCYT) Stock Price & Financial Analysis
Veracyte Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $42.70 - $45.58 |
|---|---|
| 52-Week High | $60.91 |
| 52-Week Low | $29.46 |
| Open | $43.36 |
| Volume (last close) | 1.23M |
| Average Volume (3M) | 1.37M |
| Revenue (TTM) | 561.90M |
|---|---|
| Net Income (TTM) | 114.48M |
| Free Cash Flow (TTM) | 165.46M |
| EPS (TTM) | $1.41 |
| Profit Margin | 20.37% |
| Operating Margin | 19.55% |
| Return on Equity (ROE) | 8.25% |
| Debt to Equity | 0.03 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 3.64B |
|---|---|
| Shares Outstanding | 82.06M |
| P/E Ratio (TTM) | 31.82 |
| Forward P/E | 15.73 |
| Price to Sales (P/S) | 6.48 |
| Price to Book (P/B) | 2.62 |
| EV/EBITDA | 25.38 |
| 50-Day MA | $43.63 |
|---|---|
| 200-Day MA | $42.58 |
| 1-Year Change | +23.96% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Veracyte at a Glance
As of the Oct 15, 2026 close, Veracyte (VCYT) has a market capitalization of $3.64B. The stock trades at 31.8× trailing earnings, 15.7× forward earnings and 6.5× sales. Over the trailing twelve months it earned $114.48M on revenue of $561.90M (a 20.4% profit margin) and generated $165.46M of free cash flow. Revenue grew 17.3% year over year.
As of its latest reported balance sheet, it holds $299.52M in cash and securities against $40.11M of debt, a net cash position of $259.41M.
Veracyte does not currently pay a dividend.
The share price is up 24.0% over the past year. At $44.39 (the Oct 15, 2026 close) it sits within its 52-week range of $29.45 to $60.91, above its 200-day moving average of $42.58.
Based on 13 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $58.50, 31.8% above the Oct 15, 2026 close.
Frequently Asked Questions About Veracyte
What is the current stock price for VCYT?
As of the Oct 15, 2026 close, VCYT stock trades at $44.39. The 52-week range is $29.46–$60.91, with a day range of $42.70–$45.58.
What is the P/E ratio for VCYT?
As of the Oct 15, 2026 close, Veracyte's trailing twelve-month (TTM) P/E ratio is 31.8, meaning investors pay $31.8 for every $1 of annual earnings. The forward P/E is 15.7, reflecting analyst expectations for future earnings. Veracyte operates in the Healthcare sector.
Does VCYT pay dividends?
Veracyte does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for VCYT?
Based on ratings from 13 professional analysts over the last 90 days, the consensus for VCYT is Buy. The average 12-month price target is $58.50, a 31.8% upside from the Oct 15, 2026 close of $44.39.
What is the market cap of VCYT?
As of the Oct 15, 2026 close, Veracyte's market capitalization is $3.64B, classifying it as a mid-cap company. Veracyte operates in the Healthcare sector within the Diagnostics & Research industry.